FDA Approves Label Update for Kite's Yescarta, Expanding Access to Primary Central Nervous System Lymphoma Patients.

Kite, a Gilead Company, announced that the FDA has approved a label update for Yescarta, removing limitations of use in patients with relapsed or refractory primary central nervous system lymphoma. The FDA decision is based on a positive Phase 1 investigator-sponsored study. This expansion of access to Yescarta for patients with primary central nervous system lymphoma is seen as a significant development in the treatment of this aggressive and underserved form of the disease.